Tong Xiang, Zheng Bing, Tong Qiaoyi, Liu Sitong, Peng Sifeng, Yang Xin, Fan Hong
Department of Respiratory and Critical Care Medicine, West China Hospital/West China School of Medicine, Sichuan University Chengdu, Sichuan, China.
Department of Neurological Surgery, The First Affiliated Hospital of Kunming Medical University Kunming, Yunnan, China.
Int J Clin Exp Med. 2015 Sep 15;8(9):15949-57. eCollection 2015.
The macrophage migration inhibitory factor (MIF) -173G/C gene polymorphism has been implicated in the susceptibility to cancer, but the results are not conclusive. So the aim of study to investigate the association between MIF -173G/C gene polymorphism and cancer risk by a comprehensive meta-analysis. We searched the PubMed, Embase, Wanfang and China National Knowledge Internet (CNKI) databases, with the last updated search being performed on May 24, 2015. The odds ratio (OR) and 95% confidence interval (95% CI) were used to assess the association. Statistical analysis was performed by STATA 11.0 software. Finally, 7,253 participants from 15 studies were included in the meta-analysis. The results of meta-analysis indicated the significant association between MIF -173G/C gene polymorphism and cancer susceptibility, especially in Asians (C vs.
G, OR: 1.22, 95% CI=1.00-1.50). In addition, the significant relationship between MIF -173G/C gene polymorphism and gastrointestinal tumors (CC+CG vs.
GG, OR: 1.25, 95% CI=1.05-1.50), hematological malignancy (CC+CG vs.
GG, OR: 1.27, 95% CI=1.03-1.56), gynecolgical tumors (CC vs. CG+
GG, OR: 1.51, 95% CI=1.04-2.19) risk was found. However, to avoid the "false positive report", we investigated the significant associations observed in the present meta-analysis by the false positive report probabilities (FPRPs) test. Interestingly, the results of FPRP test indicated the MIF -173G/C gene polymorphism only associated with gastrointestinal cancer and hematological malignancy risk (FPRP=0.132, 0.067 respectively) at the level of a prior probability is 0.1. Therefore, the meta-analysis suggested MIF -173G/C gene polymorphism would be a risk factor for the gastrointestinal cancer and hematological malignancy.
巨噬细胞移动抑制因子（MIF）-173G/C基因多态性与癌症易感性有关，但结果尚无定论。因此，本研究旨在通过全面的荟萃分析来探究MIF -173G/C基因多态性与癌症风险之间的关联。我们检索了PubMed、Embase、万方和中国知网（CNKI）数据库，最后一次更新检索于2015年5月24日进行。采用比值比（OR）和95%置信区间（95%CI）来评估关联。使用STATA 11.0软件进行统计分析。最终，15项研究中的7253名参与者被纳入荟萃分析。荟萃分析结果表明，MIF -173G/C基因多态性与癌症易感性之间存在显著关联，尤其是在亚洲人群中（C vs. G，OR：1.22，95%CI = 1.00 - 1.50）。此外，还发现MIF -173G/C基因多态性与胃肠道肿瘤（CC + CG vs. GG，OR：1.25，95%CI = 1.05 - 1.50）、血液系统恶性肿瘤（CC + CG vs. GG，OR：1.27，95%CI = 1.03 - 1.56）、妇科肿瘤（CC vs. CG + GG，OR：1.51，95%CI = 1.04 - 2.19）风险之间存在显著关系。然而，为避免“假阳性报告”，我们通过假阳性报告概率（FPRP）检验对本荟萃分析中观察到的显著关联进行了研究。有趣的是，FPRP检验结果表明，在先验概率为0.1的水平下，MIF -173G/C基因多态性仅与胃肠道癌和血液系统恶性肿瘤风险相关（FPRP分别为0.132和0.067）。因此，荟萃分析表明MIF -173G/C基因多态性可能是胃肠道癌和血液系统恶性肿瘤的一个风险因素。
